STOK

Stoke Therapeutics, Inc. is a pioneering biopharmaceutical company based in Bedford, Massachusetts, focused on developing groundbreaking antisense oligonucleotide (ASO) therapies to address the root causes of severe genetic disorders. Leveraging its proprietary technology platform, the company is committed to advancing genetic medicine through innovative research and development initiatives. With a strong pipeline of ASO therapies and a clear vision for transforming patient care, Stoke Therapeutics presents a compelling investment opportunity for institutional investors interested in the evolving landscape of genetic therapeutics.